Trials / Terminated
TerminatedNCT03478293
iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications
A Prospective Evaluation of the Second Generation iStent Inject in Open-Angle Glaucoma Subjects on Two Preoperative Topical Ocular Hypotensive Medications
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Glaukos Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.
Detailed description
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications. Outcomes will be evaluated at 12 and 24 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | iStent inject surgery | Micro-invasive glaucoma surgery (MIGS) to implant iStent inject |
Timeline
- Start date
- 2018-02-27
- Primary completion
- 2020-12-30
- Completion
- 2020-12-30
- First posted
- 2018-03-27
- Last updated
- 2022-09-09
Locations
1 site across 1 country: Brazil
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03478293. Inclusion in this directory is not an endorsement.